When the COVID-19 pandemic shut down research laboratories across the country, several labs at Boston Children’s Hospital geared up, including that of Wesley Wong, PhD. He and his team responded to the threat by developing a new, easy diagnostic test for COVID-19.
“Our technology, a DNA nanoswitch, is a new way of probing a test sample for evidence of infection,” says Wong, of the Program in Cellular and Molecular Medicine (PCMM) at Boston Children’s, Harvard University, and the Wyss Institute. Wong and his colleagues have been developing DNA nanoswitch technology for several years, so they were able to pivot quickly to apply it to COVID-19 diagnosis.
What is a nanoswitch?
- DNA nanoswitches represent a new diagnostic technology built on a scaffold of DNA.
- They undergo a shape change after binding to their target, flipping from a long linear ‘off’ state to a looped ‘on’ state.
- In development for several years, the technology is now being used to develop tests to detect COVID-19 RNA, proteins, and antibodies.
- Tests show the concept is promising in real life COVID-19 serum samples.
The DNA nanoswitch starts with a piece of single-strand DNA. Attached to either end of that DNA are compounds that interact with molecules that a researcher wants to study — such as antibodies to a protein made by a virus.
Once added to a blood serum sample, the DNA/antibody nanoswitches float along as sentries looking for their targets. Once they find them, the antibodies bind tightly. The bond between the pair of antibodies and the protein causes the DNA to change shape, shifting to a closed circle or loop shape. If no target is found, the DNA strand remains open in an unlooped position.
Detecting virus, antigens, or antibodies
Wong’s nanoswitch technology, which is not yet used yet used clinically, has shown promise in research studies for other diseases, including detection of prostate specific antigen, a marker of prostate health.
For COVID-19, Wong is engineering a trifecta of DNA nanoswitches. They can detect the spike protein of the SARS-CoV-2 virus that causes COVID-19, antibodies produced after exposure to the virus, or RNA made by the virus itself.
“Used together on a single sample, one could theoretically detect the presence of the virus during an active infection or antibodies produced afterwards,” says Wong.
Using common lab tools
Test results are read out by a simple gel electrophoresis system, a common analytical tool in many laboratories that sorts DNA and proteins by size and shape based on their downward movement through a gel. With a positive result — a closed loop — the sample seems to get caught and slows down, staying higher in the gel. A negative result passes through the gel to the bottom.
“The gel electrophoresis technique means the test can be done without a lot of expensive equipment and skilled technicians, and an answer can be available fairly quickly,” says Wong.
But Wong envisions simplifying things even further — especially as a rapid, on-site COVID-19 testing is needed more than ever.
“The ultimate goal would be to have something that is as easy as a pee stick, but as sophisticated and accurate as a laboratory system,” he says.
Testing begins in human samples
In early summer, Wong began collaborating with Stephen Elledge, PhD, at Harvard Medical School to test the COVID-19 DNA nanoswitch using human specimens. The rapid test they are developing will not only detect the presence of COVID-19 antibodies, but also provide more information about those antibodies.
“We hope to get some insight into how the immune system responds to infection or vaccination, and maybe even identify the presence of antibodies capable of killing, or neutralizing the virus,” says Wong. Preliminary results on patient serum samples show the concept is promising.
Funding expedites development
Given the continuing need for COVID-19 testing, several organizations have stepped in with funds to expedite the work. In May, Wong and Ken Halvorsen — now at the University at Albany RNA Institute and formerly a post-doctoral research fellow in Wong’s lab — received funding from the National Science Foundation to jointly develop and test DNA nanoswitches for rapid point-of-care testing for COVID-19 RNA. Wong also receives support from the Massachusetts Consortium on Pathogen Readiness (MassCPR) and the Massachusetts Life Sciences Center (MLSC) to develop COVID-19 DNA nanoswitches that can detect the viral spike protein and antibodies.
Read more about COVID-19 research at Boston Children’s Hospital
Related Posts :
Pregnant mothers who get COVID-19 vaccines are also protecting their babies
Recent studies have shown that COVID-19 vaccination is safe for expectant mothers and can protect them against infection, severe illness, ...
Previous COVID-19 or MIS-C does not protect kids from Omicron￼
You would think that having had COVID-19 once, you’d have antibodies that would protect you against repeat infections. But ...
COVID-19’s devastating toll: An increase in adolescent suicides and mental health crises
The past decade has seen worrisome increases in self-harm, suicidal ideation, and suicide attempts among adolescents. Two new studies from ...
Nurses Week 2022: Leading an enterprise-wide response to COVID-19
The Infection Prevention Control (IPC) team at Boston Children’s Hospital plays an important role in the management of all ...